Compare NNBR & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNBR | HURA |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 144.3M |
| IPO Year | 1996 | N/A |
| Metric | NNBR | HURA |
|---|---|---|
| Price | $3.00 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 786.5K | 480.9K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $770,657,000.00 | N/A |
| Revenue This Year | $8.60 | N/A |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.41 |
| 52 Week High | $3.24 | $3.90 |
| Indicator | NNBR | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 53.21 |
| Support Level | $2.17 | $2.15 |
| Resistance Level | $3.24 | $2.68 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 66.94 | 70.73 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with materials science expertise to design and manufacture high-precision components and solutions. The company operates through two segments: Mobile Solutions, which generates maximum revenue and focuses on the automotive, general industrial, and medical end markets, manufacturing tight-tolerance components used in battery electric, hybrid electric, and internal combustion engine vehicles, braking, transmissions, fuel systems, HVAC, and diesel systems; and Power Solutions, which focuses on the electrical, general industrial, automotive, medical, and aerospace and defense end markets and manufactures high-precision metal components, assemblies, contact assemblies, and precision stampings.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.